Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure

Hypertension

Volumn 56, Issue 5, 2010, Pages 847-851

  Shibao, Cyndya ^a   Okamoto, Luis E ^a   Gamboa, Alfredo ^a   Yu, Chang ^b   Diedrich, Andre' ^a   Raj, Satish R ^a   Robertson, David ^a   Biaggioni, Italo ^a  

^a Autonomic Dysfunction Center   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

autonomic drugs; autonomic failure; dysautonomia; orthostatic hypotension; pyridostigmine bromide

Indexed keywords

PYRIDOSTIGMINE; YOHIMBINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR;

ADULT; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART RATE; HUMAN; MALE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STANDING; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; ANALYSIS OF VARIANCE; COMPARATIVE STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PURE AUTONOMIC FAILURE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; ANALYSIS OF VARIANCE; BLOOD PRESSURE; CHOLINESTERASE INHIBITORS; CROSS-OVER STUDIES; FEMALE; HEART RATE; HUMANS; HYPOTENSION, ORTHOSTATIC; MALE; MIDDLE AGED; PURE AUTONOMIC FAILURE; PYRIDOSTIGMINE BROMIDE; SINGLE-BLIND METHOD; YOHIMBINE;

EID: 78149240157     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.154898     Document Type: Article

References (20)

1. Shibao C, Gamboa A, Diedrich A, Biaggioni I. Management of hypertension in the setting of autonomic failure: a pathophysiological approach. Hypertension. 2005;45:469-476.
2. Shear L. Orthostatic hypotension: treatment with sodium chloride and sodium retaining steroid hormones. Arch Intern Med. 1968;122:467-471.
3. Frick MH. 9-α-Fluorohydrocortisone in the treatment of postural hypotension. Acta Med Scand. 1966;179:293-299.
4. Jankovich J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, Rubin M, Fouad-Tarazi FM. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with Midodrine. Am J Med. 1993;95:38-48.
5. Kaufmann H, Brannan T, Krakoff L, Yahr MD, Mandeli J. Treatment of orthostatic hypotension due to autonomic failure with a peripheral α-adrenergic agonist (midodrine). Neurology. 1988;38:951-956.
6. Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, Low PA. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998;51:120-124.
7. Freeman R. Treatment of orthostatic hypotension. Semin Neurol. 2003;23:435-442.
8. Vagaonescu TD, Saadia D, Tuhrim S, Phillips RA, Kaufmann H. Hypertensive cardiovascular damage in patients with primary autonomic failure. Lancet. 2000;26:725-726.
9. Chobanian AV, Volicer L, Tifft CP, Gavras H, Liang CS, Faxon D. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med. 1979;301:68-73.
10. Singer W, Sandroni P, Opfer-Gehrking TL, Suarez GA, Klein CM, Hines S, O'Brien PC, Slezak J, Low PA. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006;63:513-518.
11. Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2003;74:1294-1298.
12. Killian TJ, Robertson D, Biaggioni I, Haile V, Biscaia I, Robertson RM. Sympathetic nervous system function in man is enhanced by acetylcholinesterase inhibition. Circulation. 1990;82(suppl): III-636.
13. Biaggioni I, Robertson RM, Robertson D. Manipulation of norepinephrine metabolism with yohimbine in the treatment of autonomic failure. J Clin Pharmacol. 1994;34:418-423.
14. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurol. 1996;46:1470.
15. Onrot J, Goldberg MR, Biaggioni I, Wiley R, Hollister AS, Robertson D. Oral yohimbine in human autonomic failure. Neurology. 1987;37:215-220.
16. Jordan J, Shannon JR, Biaggioni I, Norman R, Black BK, Robertson D. Contrasting actions of pressor agents in severe autonomic failure. Am J Med. 1998;105:116-124.
17. Sharabi Y, Eldadah B, Li ST, Dendi R, Pechnik S, Holmes C, Goldstein DS. Neuropharmacologic distinction of neurogenic orthostatic hypotension syndromes. Clin Neuropharmacol. 2006;29:97-105.
18. Jordan J, Shannon JR, Black BK, Lance RH, Squillante MD, Costa F, Robertson D. N (N)-nicotinic blockade as an acute human model of autonomic failure. Hypertension. 1998;31:1178-1184.
19. Goldberg MR, Robertson D. Evidence for the existence of vascular α2-adrenergic receptors in humans. Hypertension. 1984;6:551-556.
20. Robertson D, Goldberg MR, Onrot J, Hollister AS, Thompson JC, Wiley R, Robertson RM. Isolated failure of autonomic noradrenergic neurotransmission: evidence for impaired β-hydroxylation of dopamine. N Engl J Med. 1986;314:1494-1497.